Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jack Feehan, Ahmed Al Saedi & Gustavo Duque. (2019) Targeting fundamental aging mechanisms to treat osteoporosis. Expert Opinion on Therapeutic Targets 23:12, pages 1031-1039.
Read now
Read now
Josep Darbà, Nuria Pérez-Álvarez, Lisette Kaskens, Susana Holgado-Pérez, Jill Racketa & Javier Rejas. (2013) Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain. ClinicoEconomics and Outcomes Research 5, pages 327-336.
Read now
Read now
Santiago Palacios. (2010) Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Current Medical Research and Opinion 26:7, pages 1553-1563.
Read now
Read now
T. J. de Villiers. (2010) Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. Climacteric 13:3, pages 210-218.
Read now
Read now
Daniel S Sem. (2004) Chemical proteomics from a nuclear magnetic resonance spectroscopy perspective. Expert Review of Proteomics 1:2, pages 165-178.
Read now
Read now
Articles from other publishers (22)
Agnidipta Das, Kanamarlapudi Joshna Lavanya, Nandini, Kamalpreet Kaur & Vikas Jaitak. (2023) Effectiveness of Selective Estrogen Receptor Modulators in Breast
Cancer Therapy: An Update. Current Medicinal Chemistry 30:29, pages 3287-3314.
Crossref
Crossref
Zhenlin Liang, Lijuan Liu, Yanyu Zhou, Wukun Liu & Yunlong Lu. (2023) Research Progress on Bioactive Metal Complexes against ER-Positive Advanced Breast Cancer. Journal of Medicinal Chemistry 66:4, pages 2235-2256.
Crossref
Crossref
Samy A.F. Morad & Myles C. Cabot. (2015) Tamoxifen regulation of sphingolipid metabolism—Therapeutic implications. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1851:9, pages 1134-1145.
Crossref
Crossref
Chanchal Kumar & Alain J. van Gool. 2013. Comprehensive Biomarker Discovery and Validation for Clinical Application. Comprehensive Biomarker Discovery and Validation for Clinical Application
3
39
.
Paolo Oliva, Chiara Roncoroni, Enrico Radaelli, Electra Brunialti, Nicoletta Rizzi, Marcella De Maglie, Eugenio Scanziani, Giulia Piaggio, Paolo Ciana, Barry Komm & Adriana Maggi. (2013) Global Profiling of TSEC Proliferative Potential by the Use of a Reporter Mouse for Proliferation. Reproductive Sciences 20:2, pages 119-128.
Crossref
Crossref
S. Silverman & C. Christiansen. (2012) Individualizing osteoporosis therapy. Osteoporosis International 23:3, pages 797-809.
Crossref
Crossref
Barry S. Komm, Fay Vlasseros, Rana Samadfam, Luc Chouinard & Susan Y. Smith. (2011) Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 49:3, pages 376-386.
Crossref
Crossref
Harry K Genant. (2011) Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Menopause International 17:2, pages 44-49.
Crossref
Crossref
Gloria Bachmann, Uel Crosby, Robert A. Feldman, Sheila Ronkin & Ginger D. Constantine. (2011) Effects of bazedoxifene in nonflushing postmenopausal women. Menopause 18:5, pages 508-514.
Crossref
Crossref
Akira Itabashi, Kousei Yoh, Arkadi A Chines, Takami Miki, Masahiko Takada, Hiroshi Sato, Itsuo Gorai, Toshitsugu Sugimoto, Hideki Mizunuma, Hiroshi Ochi, Ginger D Constantine & Hiroaki Ohta. (2011) Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis. Journal of Bone and Mineral Research 26:3, pages 519-529.
Crossref
Crossref
T. J. de Villiers, A. A. Chines, S. Palacios, P. Lips, A. Z. Sawicki, A. B. Levine, C. Codreanu, N. Kelepouris & J. P. Brown. (2010) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporosis International 22:2, pages 567-576.
Crossref
Crossref
L. Xu, K.-S. Tsai, G. S. Kim, Y. Wu, P. Vincendon, A. A. Chines & G. D. Constantine. (2010) Efficacy and safety of bazedoxifene in postmenopausal Asian women. Osteoporosis International 22:2, pages 559-565.
Crossref
Crossref
J. Christopher Gallagher & Jeffrey P. Levine. (2011) Preventing osteoporosis in symptomatic postmenopausal women. Menopause 18:1, pages 109-118.
Crossref
Crossref
Claus Christiansen, Charles H ChesnutIIIIII, Jonathan D Adachi, Jacques P Brown, César E Fernandes, Annie WC Kung, Santiago Palacios, Amy B Levine, Arkadi A Chines & Ginger D Constantine. (2010) Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskeletal Disorders 11:1.
Crossref
Crossref
Toine F.H. Bovee, Mario Thevis, Astrid R.M. Hamers, Ad A.C.M. Peijnenburg, Michel W.F. Nielen & Willem G.E.J. Schoonen. (2010) SERMs and SARMs: Detection of their activities with yeast based bioassays. The Journal of Steroid Biochemistry and Molecular Biology 118:1-2, pages 85-92.
Crossref
Crossref
David F Archer. 2008. Endometrium, The. Endometrium, The
761
770
.
Sabine Rehm, Henk A. Solleveld, Samm T. Portelli & Patrick J. Wier. (2007) Histologic changes in ovary, uterus, vagina, and mammary gland of mature beagle dogs treated with the SERM idoxifene. Birth Defects Research Part B: Developmental and Reproductive Toxicology 80:3, pages 225-232.
Crossref
Crossref
Tara E. Sutherland, Michael Schuliga, Trudi Harris, Bedrich L. Eckhardt, Robin L. Anderson, Lilly Quan & Alastair G. Stewart. (2005) 2-Methoxyestradiol Is an Estrogen Receptor Agonist That Supports Tumor Growth in Murine Xenograft Models of Breast Cancer. Clinical Cancer Research 11:5, pages 1722-1732.
Crossref
Crossref
C K Osborne, A Wakeling & R I Nicholson. (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. British Journal of Cancer 90:S1, pages S2-S6.
Crossref
Crossref
Chang Bai, Azriel Schmidt & Leonard P. Freedman. (2003) Steroid Hormone Receptors and Drug Discovery: Therapeutic Opportunities and Assay Designs. ASSAY and Drug Development Technologies 1:6, pages 843-852.
Crossref
Crossref
Israel Yoles, Yariv Yogev, Yair Frenkel, Ravit Nahum, Michael Hirsch & Boris Kaplan. (2003) Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 10:6, pages 522-525.
Crossref
Crossref
D. Somjen & I. Yoles. (2014) DT56a stimulates creatine kinase specific activity in vascular tissues of rats. Journal of Endocrinological Investigation 26:10, pages 966-971.
Crossref
Crossref